Detection of Epidermal Growth Factor Receptor Mutation in Transbronchial Needle Aspirates of Non-Small Cell Lung Cancer

Horiike, Atsushi; Kimura, Hideharu; Nishio, Kazuto; Ohyanagi, Fumiyoshi; Satoh, Yukitoshi; Okumura, Sakae; Ishikawa, Yuichi; Nakagawa, Ken; Horai, Takeshi; Nishio, Makoto

doi:10.1378/chest.06-1673

Cited by 93 publications

(73 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other PCR-based techniques, such as peptide nucleic acid (PNA)-locked PCR clamping (28), allele-specific quantitative real-time PCR (29), scorpion ARMS (TheraScreen; ref. 30), have been developed for sensitive detection of somatic mutations. The main limitation of these techniques is that they require multiple PCRs and therefore an adequate amount of gDNA, not always available when working with cytologic samples.…”

Section: Discussionmentioning

confidence: 99%

Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing

Buttitta

Felicioni

Grammastro

et al. 2013

Clinical Cancer Research

110

View full text Add to dashboard Cite

Purpose: The therapeutic choice for patients with lung adenocarcinoma depends on the presence of EGF receptor (EGFR) mutations. In many cases, only cytologic samples are available for molecular diagnosis. Bronchoalveolar lavage (BAL) and pleural fluid, which represent a considerable proportion of cytologic specimens, cannot always be used for molecular testing because of low rate of tumor cells.Experimental Design: We tested the feasibility of EGFR mutation analysis on BAL and pleural fluid samples by next-generation sequencing (NGS), an innovative and extremely sensitive platform. The study was devised to extend the EGFR test to those patients who could not get it due to the paucity of biologic material. A series of 830 lung cytology specimens was used to select 48 samples (BAL and pleural fluid) from patients with EGFR mutations in resected tumors. These samples included 36 cases with 0.3% to 9% of neoplastic cells (series A) and 12 cases without evidence of tumor (series B). All samples were analyzed by Sanger sequencing and NGS on 454 Roche platform. A mean of 21,130 AE 2,370 sequences per sample were obtained by NGS.Results: In series A, EGFR mutations were detected in 16% of cases by Sanger sequencing and in 81% of cases by NGS. Seventy-seven percent of cases found to be negative by Sanger sequencing showed mutations by NGS. In series B, all samples were negative for EGFR mutation by Sanger sequencing whereas 42% of them were positive by NGS.Conclusions: The very sensitive EGFR-NGS assay may open up to the possibility of specific treatments for patients otherwise doomed to re-biopsies or nontargeted therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing

Buttitta

Felicioni

Grammastro

et al. 2013

Clinical Cancer Research

110

View full text Add to dashboard Cite

show abstract

“…In these studies, EGFR mutations have been detected in bronchoscopic biopsy and cytology specimens [25,26], percutaneous and pleural biopsy specimens, effusion cell blocks and blood samples [8,27,28]. Cases in which EGFR mutations were identified in TBNA and EBUS-TBNA samples have also been reported recently [13,14].…”

Section: Discussionmentioning

confidence: 99%

“…Nonsurgical approaches to tissue sampling are required in order to increase the proportion of cases in which tumour tissue is available for genetic examination. SHIH et al [8] reported that the presence of EGFR mutations in needle aspiration samples of lung tumours correlates with a better outcome in these patients, and other studies have since demonstrated the feasibility of transbronchial needle aspiration (TBNA) of tumours reaching the mediastinum or located near the main bronchus in order to obtain samples for mutation studies [13]. More recently, NAKAJIMA et al [14] demonstrated that EGFR mutations could be detected in samples from metastatic lymph nodes obtained using endobronchial ultrasound (EBUS)-guided TBNA (EBUS-TBNA) in 43 patients suffering from lung cancer.…”

mentioning

confidence: 99%

Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations

García-Olivé¹,

Monsó²,

Andreo³

et al. 2009

Eur Respir J

121

View full text Add to dashboard Cite

The presence of somatic mutations of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene in patients with advanced nonsmall cell lung cancer (NSCLC) correlates with a good response to tyrosine kinase inhibitors. The usefulness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the detection of EGFR mutations in cells recovered from malignant mediastinal nodes in patients with NSCLC was assessed.All patients with lung adenocarcinoma or unspecified NSCLC referred for staging with EBUS-TBNA were included. Nodes with a short-axis diameter of .5 mm were sampled, and genomic DNA from metastatic tumour cells was obtained for analysis of exons 19 and 21. The impact of sampling on management was assessed.EGFR gene analysis of the EBUS-TBNA sample was feasible in 26 (72.2%) out of the 36 patients with lymph node metastasis. Somatic mutations of the EGFR gene were detected in tissue obtained through EBUS-TBNA in two (10%) out of 20 patients with metastasic lung adenocarcinoma.Malignant tissue samples obtained by EBUS-TBNA from patients with nodal metastasis of NSCLC are suitable for the detection of EGFR mutations in most cases, and this technique demonstrates mutated neoplastic cells in a tenth of patients with adenocarcinoma.

show abstract

“…Several recent studies have demonstrated that expression of certain genes is associated with response to cisplatin-based therapy and survival [14][15][16]. Moreover, by utilising transbronchial needle lymph node aspiration samples, several groups have shown that evaluation of the epidermal growth factor receptor status can be performed [17][18][19][20]. Therefore, with adjustable-depth endobronchial ultrasound needle transbronchial needle lymph node aspiration, the potential may exist for greater tissue acquisition to be used for molecular and genetic analysis to guide therapy in unresectable patients, but at the potential cost of increased infection risk.…”

Section: Infectious Complications From Ebus-tbna Ar Haasmentioning

confidence: 99%

Infectious complications from full extension endobronchial ultrasound transbronchial needle aspiration

2009

Eur Respir J

110

View full text Add to dashboard Cite

The development of a convex probe endobronchial ultrasound (CP-EBUS) videobronchoscope to allow real-time transbronchial needle aspiration (TBNA) has been a significant advance in minimally invasive lung cancer staging and diagnosis. Several recent studies have demonstrated CP-EBUS-TBNA to have recovery rivalling that of the current gold standard, cervical mediastinoscopy. These same studies have indicated that the safety of this procedure has no reported complications.The present case study presents two infectious complications from full extension endobronchial ultrasound transbronchial needle aspiration and discusses possible aetiologies of these infections, as well as implications for future application of this technology.

show abstract

Detection of Epidermal Growth Factor Receptor Mutation in Transbronchial Needle Aspirates of Non-Small Cell Lung Cancer

Cited by 93 publications

References 29 publications

Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing

Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing

Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations

Infectious complications from full extension endobronchial ultrasound transbronchial needle aspiration

Contact Info

Product

Resources

About